Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-28T12:14:33.612Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats

Published online by Cambridge University Press:  06 August 2013

Kinga Burda-Malarz ,
Krzysztof Kus ,
Piotr Ratajczak ,
Anna Czubak ,
Elżbieta Nowakowska ,
Łukasz Jędrzejewski  and
Czesław Sadowski
Kinga Burda-Malarz*
Affiliation:
Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Poznań, Poland
Krzysztof Kus
Affiliation:
Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Poznań, Poland
Piotr Ratajczak
Affiliation:
Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Poznań, Poland
Anna Czubak
Affiliation:
Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Poznań, Poland
Elżbieta Nowakowska
Affiliation:
Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Poznań, Poland
Łukasz Jędrzejewski
Affiliation:
Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Poznań, Poland
Czesław Sadowski
Affiliation:
Department of Toxicology, University of Medical Sciences in Poznań, Poznań, Poland
*
Dr. Kinga Burda-Malarz, Department of Pharmacoeconomics and Social Pharmacy, University of Medical Sciences in Poznań, Dąbrowskiego 79, PL 60-529 Poznań, Poland. Tel: +480618546920; Fax: +480618546894; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction and aims

Dependence on ethanol increases the risk of depression in patients and leads to a damage and deficiencies of brain function, which manifest in cognitive functions impairment. Aripiprazole (ARI) is an atypical antipsychotic drug, which has also been shown to have a beneficial effect on cognitive function. Results of many studies show that, for ARI's antidepressant effect to manifest itself, it is necessary to use a combined therapy with a drug from the group of selective serotonin reuptake inhibitors (SSRIs). The aim of this paper was to assess the antidepressant and impact of ARI on spatial memory in alcohol-preferring rats (EtNPRs).

Design and methods

In our study, we used Porsolt's forced swimming test (antidepressant effect) and Morris water maze test. The tests have been conducted upon administration of ARI (6 mg/kg i.p.), fluoxetine (FLX; 5 mg/kg p.o.) and combined administration of both drugs in alcohol-dependent rats.

Results

The results of behavioural tests carried out have shown a lack of antidepressant and procognitive effects of either ARI or FLX in EtPRs after acute and chronic treatment. Combined administration of both drugs would lead to spatial memory deterioration in the study animals.

Discussion and conclusions

Our results suggest that ARI applied in the experiment had no antidepressant effect and failed to improve spatial memory in study rats. Potential antidepressant and procognitive properties of this drug resulting from its mechanism of action encourage attempts (design) of further research aimed at developing a dose, which will show such effects in alcohol-preferring animals.

Keywords

alcohol-preferring ratsaripiprazolecognitive functionfluoxetine
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 26 , Issue 2 , April 2014 , pp. 112 - 119
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Conway, KP, Compton, W, Stinson, FSet al. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug of use disorders: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiat 2006;67:247–257.CrossRefGoogle ScholarPubMed
2.Kessler, RC, Crum, RM, Warner, LAet al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313–321.CrossRefGoogle ScholarPubMed
3.Sullivan, EV, Deshmukh, A, De Rosa, Eet al. Striatal and forebrain nuclei volumes: contribution to motor function and working memory deficits in alcoholism. Biol Psychiatry 2005;57:768–776.CrossRefGoogle ScholarPubMed
4.Nordmann, R. Alcohol and antioxidant systems. Alcohol 1994;29:513–522.Google ScholarPubMed
5.Ratti, MT, Giardini, A, Soragna, D. Chronic alcoholism and the frontal lobe: which executive functions are impaired? Acta Neurol Scand 2002;105:276–281.CrossRefGoogle Scholar
6.Marder, SR, McQuade, RD, Stock, Eet al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123–136.CrossRefGoogle ScholarPubMed
7.Potkin, SG, Saha, AR, Kujawa, MJet al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–690.CrossRefGoogle ScholarPubMed
8.Renard, CE, Fiocco, AJ, Clenet, Fet al. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 2001;159:42–50.CrossRefGoogle ScholarPubMed
9.Bourin, M, Chenu, F, Prica, Cet al. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacol 2009;206:97–107.CrossRefGoogle ScholarPubMed
10.Kamei, J, Miyata, S, Sunohara, Tet al. Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci 2008;108:381–384.CrossRefGoogle ScholarPubMed
11.Miko̡ajczak, P, Okulicz-Kozaryn, I, Kaminska, Eet al. Lack of ifenprodil anxiolytic activity after its multiple treatment in chronically ethanol-treated rats. Alcohol Alcohol 2003;38:310–315.CrossRefGoogle Scholar
12.Okulicz-Kozaryn, I, Miko̡ajczak, P, Kamińska, Eet al. Effect of naltrexone administration on short-term memory in chronically ethanol-treated outbred rats. Alcohol Alcohol 2004;39:14–19.CrossRefGoogle ScholarPubMed
13.Porsolt, RD, Anton, G, Blavet, Net al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379–391.CrossRefGoogle ScholarPubMed
14.Morris, R. Development of a water-maze procedure for studying spatial learning in a rat. J Neurosci Methods 1984;11:47–60.CrossRefGoogle Scholar
15.Weiss, F, Porrino, LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002;22:3332–3337.CrossRefGoogle ScholarPubMed
16.Enomoto, T, Ishibashi, T, Tokuda, Ket al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186:197–207.CrossRefGoogle ScholarPubMed
17.Ishiyama, T, Tokuda, K, Ishibashi, Tet al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572:160–170.CrossRefGoogle ScholarPubMed
18.Burda, K, Czubak, A, Kus, Ket al. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 2011;63:898–907.CrossRefGoogle ScholarPubMed
19.Semba, J, Watanabe, A, Kito, Set al. Behavioural and neurochemical effects of, a novel antipsychotic drug OPC- 14597, on dopaminergic mechanisms in rat brain. Neuropharmacol 1995;34:785–791.CrossRefGoogle ScholarPubMed
20.Preskorn, SH. Relating clinical trials to psychiatric practice: Part I. The case of a 13-year old on aripiprazole and fluoxetine. J Psychiatric Pract 2003;9:307–313.CrossRefGoogle ScholarPubMed
21.Dyr, W, Ćwik, M, Kostowski, W. Importance of selected lines of EHP and WLP rats in studies on mechanism of ethanol effect. Alkoholizm i Narkomania 2009;22:177–187.Google Scholar
22.Maj, J, Rogoz, Z. Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol J Pharmacol 1999;51:471–475.Google ScholarPubMed
23.Pae, CU, Serretti, A, Patkar, AA. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367–388.CrossRefGoogle ScholarPubMed
24.Joca, SR, Skalisz, LL, Beijamini, Vet al. The antidepressant-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 2000;10:223–328.CrossRefGoogle Scholar
25.Renard, CE, Dailly, E, David, DJet al. Neurochemical changes following the mouse forced swimming test but not the tail suspension test. Int J Neuropsychopharmacol 2003;17:449–455.Google Scholar
26.Renard, CE, Dailly, E, Nic Dhonnchadha, BAet al. Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test? Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1255–1259.CrossRefGoogle ScholarPubMed
27.Snigdha, S, Neill, J. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 2008;191:26–31.CrossRefGoogle Scholar
28.Sams-Dodd, F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 1996;7:3–23.CrossRefGoogle ScholarPubMed
29.Urban, JD, Vargas, GA, Zastrow, MVet al. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007;32:67–77.CrossRefGoogle ScholarPubMed